Peripheral neuropathy and monoclonal gammopathy of undetermined significance : A population-based study including 15,351 cases and 58,619 matched controls

Rögnvaldsson, Sæmundur; Steingrímsson, Vilhjálmur; Turesson, Ingemar; Björkholm, Magnus; Landgren, Ola; Kristinsson, Sigurður Yngvi

Opin vísindi
→
IRIS
→
IRIS
→
Skoða verk

dc.contributor	Landspitali - The National University Hospital of Iceland
dc.contributor	University of Iceland
dc.contributor.author	Rögnvaldsson, Sæmundur
dc.contributor.author	orcid.org/0000-0002-9385-2960 Steingrímsson, Vilhjálmur
dc.contributor.author	Turesson, Ingemar
dc.contributor.author	Björkholm, Magnus
dc.contributor.author	Landgren, Ola
dc.contributor.author	Kristinsson, Sigurður Yngvi
dc.date.accessioned	2022-08-25T01:01:48Z
dc.date.available	2022-08-25T01:01:48Z
dc.date.issued	2020-11
dc.identifier.citation	Rögnvaldsson , S , Steingrímsson , V , Turesson , I , Björkholm , M , Landgren , O & Kristinsson , S Y 2020 , ' Peripheral neuropathy and monoclonal gammopathy of undetermined significance : A population-based study including 15,351 cases and 58,619 matched controls ' , Haematologica , vol. 105 , no. 11 , pp. 2679-2681 . https://doi.org/10.3324/haematol.2019.239632
dc.identifier.issn	0390-6078
dc.identifier.other	35020245
dc.identifier.other	35daa71c-1f5f-42c3-b9cf-14fa39c0848c
dc.identifier.other	85088411974
dc.identifier.other	32054650
dc.identifier.uri	https://hdl.handle.net/20.500.11815/3346
dc.description	Funding Information: this research was supported by grants from the University of Iceland Research Fund, Icelandic Centre for Research (RANNIS), Landspitali University Hospital Research Fund, and Karolinska Institutet Foundations. Funding support for this publication was provided by the Memorial Sloan Kettering Core Grant (P30 CA008748) and the Perelman Family Foundation in collaboration with the Multiple Myeloma Research Foundation (MMRF) for OL. SR is a PhD candidate at the University of Iceland and this work is submitted in partial fulfilment of the requirement for a PhD. Funding Information: 1Faculty of Medicine, University of Iceland, Reykjavík, Iceland; 2Skåne University Hospital, Malmö/Lund, Sweden; 3Department of Medicine, Karolinska University Hospital Solna and Institutet, Stockholm, Sweden and 4Myeloma Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY, USA Correspondence: SAEMUNDUR ROGNVALDSSON - saer2@hi.is doi:10.3324/haematol.2019.239632 Funding: this research was supported by grants from the University of Iceland Research Fund, Icelandic Centre for Research (RANNIS), Landspitali University Hospital Research Fund, and Karolinska Institutet Foundations. Funding support for this publication was provided by the Memorial Sloan Kettering Core Grant (P30 CA008748) and the Perelman Family Foundation in collaboration with the Multiple Myeloma Research Foundation (MMRF) for OL. SR is a PhD candidate at the University of Iceland and this work is submitted in partial fulfilment of the requirement for a PhD.
dc.format.extent	3
dc.format.extent	490118
dc.format.extent	2679-2681
dc.language.iso	en
dc.relation.ispartofseries	Haematologica; 105(11)
dc.rights	info:eu-repo/semantics/openAccess
dc.subject	Hematology
dc.title	Peripheral neuropathy and monoclonal gammopathy of undetermined significance : A population-based study including 15,351 cases and 58,619 matched controls
dc.type	/dk/atira/pure/researchoutput/researchoutputtypes/contributiontojournal/letter
dc.description.version	Peer reviewed
dc.identifier.doi	10.3324/haematol.2019.239632
dc.relation.url	http://www.scopus.com/inward/record.url?scp=85088411974&partnerID=8YFLogxK
dc.contributor.department	Internal Medicine and Emergency Services
dc.contributor.department	Faculty of Medicine
dc.contributor.department	Cancer Center